Document |
Document Title |
JP4028607B2 |
To obtain a new cephalosporin derivative being the specific one, having a wide range antimicrobial spectrum and a strong antibacterial activities and useful as an antimicrobial agent effective in methicillin resistant Staphylococcus aure...
|
JPWO2005085258A1 |
formula: [Chemical 1](In the formula, A may be substituted lower alkylene (substituent: mono or di-lower alkyl, lower alkylidene, or lower alkylene with 2 or more carbon atoms); Z+Is one of the following: [Chemical 2](In the formula, R1A...
|
JP4022070B2 |
The present invention relates to a new crystalline aminothiazole derivative represented by the following formula (I) which is very useful for the preparation of cephalosporin antibiotics, including ceftazidime and cefixime, etc:wherein R...
|
JP4018546B2 |
A 3-(Z)-propenyl cephem compound is selectively prepared by reacting a phosphoranylidene cephem compound with acetaldehyde in the presence of a base in a solvent mixture comprising diethyl ether, formula (I), wherein R is a carboxyl prot...
|
JPWO2005034957A1 |
According to the present invention, there is provided a solid dispersion composition which can maintain amorphous cefditoren pivoxil in a suspension for a long period of time. The present invention is a solid dispersion composition compr...
|
JP2007533724A |
A method of stabilizing pharmaceutical compositions containing cefovecin sodium salt which is in an amorphous or other disordered state is disclosed.
|
JP2007532579A |
The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-
3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorph...
|
JP2007529521A |
Compositions, methods and kits are disclosed for improved staining of a cell or tissue with a dye-conjugate that binds specifically to a particular component of the cell or tissue. The compositions, methods and kits include a polymeric m...
|
JP3994011B2 |
The invention relates to a new process for the preparation of a vinyl-pyrrolidinone cephalosporine derivative of the formula I The compound of the formula I, prepared according to the invention can be used for the treatment and prophylax...
|
JP2007528386A |
This invention relates a process for preparing a compound of formula (I) wherein R1 is para-nitrobenzyl or allyl; X is halo; as well as its isomers.
|
JP3989832B2 |
A process for producing the compound (1'benzyl-2-oxo-[1,3']-(R)-bipyrrolidinyl-3-(R,S)-yl)-triphe
nyl-phosphonium bromide which is an intermediate for antibacterial vinylpyrrolidinone-cephalosporin derivatives.
|
JP2007238596A |
To provide a process for obtaining cefepime dihydrochloride monohydrate from synthetic cefepime. A synthetic cefepime solution is bleached with carbon, sterilely filtered and treated with a concentrated hydrochloric acid to pH 0.4-0.6 at...
|
JP3948628B2 |
PCT No. PCT/KR96/00250 Sec. 371 Date May 18, 1998 Sec. 102(e) Date May 18, 1998 PCT Filed Dec. 26, 1996 PCT Pub. No. WO97/24358 PCT Pub. Date Jul. 10, 1997The present invention relates to a novel crystalline cefdinir intermediate having ...
|
JP3927808B2 |
The present invention relates to a new, simple, and easy process for preparing cephalosporin antibiotics of the following formula (I), such as ceftazidime and cefixime. The process comprises acylating a 7-amino cephalosporanic acid deriv...
|
JP3928086B2 |
A compound represented by the formula: (I) wherein Acyl represents an acyl group which can be used in the field of ß-lactams; T represents S, SO or O; the group represented by the formula: (Q) represents a heterocyclic group which may b...
|
JP3927262B2 |
To produce a specific new cephem compound capable of manifesting excellent antimicrobial activities against Gram-positive and Gram-negative bacteria including methicillin-resistant Staphylococcus aureus(MRSA) and useful as an antimicrobi...
|
JP2007131535A |
To provide an agent for suppressing the formation of a modified protein, free from hypotensive action and inducing no vitamin B6 deficiency.The agent for suppressing the formation of a modified protein uses a compound having a free or sa...
|
JP3920939B2 |
To obtain a new crystalline cephem acid addition salt with long half- life in the blood and excellent medicinal sustainability, useful for the treatment of bacterial infectious diseases. This compound is shown by formula I [(n) is 1 or 2...
|
JP2007512261A |
The present invention discloses the ²-lactamase resistant cephalosporin ester compounds represented by the following formula (I), characterized in that the structures of the compounds are composed by connecting methyl ester residue of s...
|
JP2007119484A |
To provide a new antibacterial agent of cephem compound expressing a wide antibacterial spectrum to various pathogenic bacteria.The compound is expressed by formula (I), wherein Acyl expresses an acyl applicable to the β-lactam field; T...
|
JP3914276B2 |
To obtain a specific new cephalosporin derivative having a substituted sulfonylmethyl group bonded to the 3-site of cephem ring, having a broad antibacterial spectrum and strong antibacterial action and useful for an antibacterial agent,...
|
JP3911124B2 |
A process for increasing the diastereoisomeric ratio (B/A+B), wherein B is the more apolar and A is the more polar of two diastereoisomers, of a mixture of diastereoisomers of a compound of formulathe diastereoisomers being with respect ...
|
JP2007106684A |
To provide a pharmaceutical preparation containing cefditoren pivoxil, having improved wettability with water and improved dissolution property and exhibiting high initial dissolution rate.The pharmaceutical composition comprises 0.1-10 ...
|
JP2007510709A |
The present invention relates to a process for preparation of highly pure amorphous and crystalline forms of cefditoren pivoxil and pharmaceutical compositions comprising highly pure amorphous and crystalline forms of cefditoren pivoxil....
|
JP2007077123A |
To provide a cefdinir which solves a problem that conventional crystalline cefdinir is slightly soluble in water, and has high solubility in water.The present invention relates to amorphous cefdinir which does not contain crystalline cef...
|
JP2007077137A |
To provide an industrial method for directly converting cefepime being a cephalosporin having a wide action spectrum into sterilized cefepime dihydrochloride monohydrate.The method for producing sterilized cefepime dihydrochloride monohy...
|
JP2007503447A |
The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.
|
JP3884063B2 |
A process for producing cefcapene pivoxil methanesulfonate and, with the use thereof as an intermediate, corresponding hydrochloride. There is provided methanesulfonate of the compound of the formula (?).
|
JP2007023046A |
To provide new cepham compounds having antimicrobial activities, their production method, intermediates and a pharmaceutical composition containing the cepham compounds.The antibacterial compounds are expressed by formula I [in the formu...
|
JP3872955B2 |
The present invention is concerned with new compounds of formula (I) wherein R<1> is hydrogen, C1-6-alkyl, optionally substituted by fluoro, or C3-6-cycloalkyl; R<2> is hydrogen or a group selected from -CH2C(=CHR)-COOR, -CH2OCOR, -CH(R)...
|
JP3868008B2 |
PURPOSE: To obtain a new temp. and moisture stable compd. useful as a compsn. for injection. CONSTITUTION: This dihydrate of 7-[α-(2-aminothiazol-4-yl)-α-(Z)- methoxyiminoacetamide)-3-[(1-methyl-1-pyrrolidino)methyl]-3-
cephem-4- carbo...
|
JP2006528970A |
The present invention is concerned with a novel cephem compound, with a process for the production of this compound, which process may contain or consist of fermentative steps, chemical steps, and/or biotransformation steps. A cephem com...
|
JP3863915B2 |
A new salt form of cefonicid and its method of preparation is disclosed.
|
JP3860750B2 |
7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid of formula (I) can be easily prepared by reacting 7-aminocephalosporanic acid of formula (II) with an azeotropic mixture of trimethyl borate and methanol in the presence of methanesulfon...
|
JP3856807B2 |
To provide a beta-lactamase as a reporter gene, a beta-lactamase substrate compound and uses thereof for particularly monitoring expression from a pair of expression control sequences to screen a biochemical activity. Disclosed is a reco...
|
JP3852946B2 |
PCT No. PCT/US94/01862 Sec. 371 Date Sep. 11, 1995 Sec. 102(e) Date Sep. 11, 1995 PCT Filed Mar. 7, 1994 PCT Pub. No. WO94/20505 PCT Pub. Date Sep. 15, 1994Anhydrous and crystalline free acid form of the cephalosporin antiobiotic ceftiof...
|
JP3850692B2 |
To provide a method of preparing a cephalosporin compound and an intermediate for preparation of these compound. This method cyclizes a compound of formula (III) to obtain a compound expressed by formula (II). [R1 is H, a methoxy or form...
|
JP2006525340A |
The present invention relates to carbacephem antibiotics and pharmaceutically acceptable salts thereof useful for the treatment of bacterial infections, in particular infections caused by methicillin-resistant Staphylococcus spp. bacteria.
|
JP3837439B2 |
To obtain a new cephem compound having an excellent antibacterial power, especially exhibiting a storing antibacterial activity against MRSA, high in solubility in water, low in toxicity and high in safety. For this cephen compound, a ce...
|
JP3836675B2 |
A method for preparing an alpha-oxolactam comprising, reacting a corresponding alpha-diazolactam with an oxygen donor, in the presence of a transition metal catalyst, to yield the corresponding alpha-oxolactam.
|
JP2006206529A |
To provide a method for producing a compound represented by formula (1).The compound represented by formula (2) and its salts are found out as efficient synthetic intermediates of the above-mentioned compound. [Wherein, R is H, an alkyl ...
|
JPWO2004085443A1 |
7- [2- (2-Aminothiazole-4-yl) -2-hydroxyiminoacetamide] -3-vinyl-3-cephem-4 showing a peak at the diffraction angle shown in the table below in the powder X-ray diffraction pattern. -A novel crystal (B-type crystal) of a carboxylic acid ...
|
JP3791941B2 |
PURPOSE: To obtain the subject high-purity compound important as an intermediate for cephem-based antibiotic substances useful as an oral agent in high yield according to safe and simple operations by using a specific arenyl β-lactam co...
|
JP2006515633A |
A pharmaceutically active compound having a carboxylic acid group -COOH as a part of its chemical structure which -COOH group is in the form of a carboxylic acid ester.
|
JP3777191B2 |
A cephalosporin derivative which has a substituted or unsubstituted 2-(5-thiazolyl)vinyl group at the 3-position and is represented by the following formula (I) wherein X is CH or N, R<1> is an amino group or a protected amino group, R<2...
|
JP3775836B2 |
To safely and easily produce a compound useful as a production intermediate for cephem antibiotics for oral administration in high yield and purity by reacting a specific allenyl β-lactam compound with a halogenation reagent in the pres...
|
JP3775819B2 |
PURPOSE: To obtain the subject high-purity compound useful as an antimicrobial agent having a wide range of antimicrobial spectra in high yield according to simple operations by using a specific halomethylcephem compound as a starting ra...
|
JP2006096679A |
To provide a new inexpensive manufacturing method of cefditoren.The manufacturing method of 7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamide]-3-[2-(4-
methylthiazol-5-yl)vinyl]-3-cefem-4-carboxylic acid (cefditoren) represented by form...
|
JP2006511561A |
Cefdinir crystalline salts of formula (I), in which n ranges from 1 to 3, the preparation and use thereof for the preparation and purification of cefdinir are herein disclosed. The salts of formula (I) can be obtained from cefdinir inter...
|
JP2006508984A |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|